Hesperos, Inc, is a leader in efforts to characterize an individual’s biology with human-on-a-chip microfluidic systems.
Hesperos, Inc. is a leader in efforts to characterize an individual's biology with Human-on-a-Chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational PKPD modeling of live physiological responses utilizing functional readouts from neurons, cardiac, muscle, barrier tissues and neuromuscular junctions as well as responses from liver, pancreas and barrier tissues.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 25, 2021 | Grant | $1.90M | 1 | National Institutes of Health | — | Detail |
Sep 27, 2019 | Grant | — | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |